{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T04:17:17Z","timestamp":1777004237383,"version":"3.51.4"},"reference-count":6,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,11,25]]},"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:p>A 65-year-old woman with type II diabetes mellitus complicated by non-healing ulcers with recurrent osteomyelitis was admitted for progression of cellulitis after treatment failure with an outpatient course of amoxicillin-clavulanate. She was found to have persistent osteomyelitis and started on ceftazidime for a culture documented <jats:italic>Pseudomonas aeruginosa<\/jats:italic> infection. After two parenteral doses, she had a rapid rise in liver function tests (LFTs) in a hepatocellular pattern. Due to rapid identification, all medications with potential hepatotoxicity, including ceftazidime, were discontinued and the LFTs promptly returned to baseline over 3\u2009days. Of note, the patient did not experience any symptoms of liver injury. Other causes of acute liver injury were effectively ruled out, but the case was confounded by usage of other potential hepatotoxic medications. Still, the most likely culprit was ceftazidime, a rare cause of drug induced liver injury with very few reports in the literature.<\/jats:p>","DOI":"10.1136\/bcr-2021-246571","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T11:36:23Z","timestamp":1639049783000},"page":"e246571","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Ceftazidime induced liver injury"],"prefix":"10.1136","volume":"14","author":[{"given":"Tayyab","family":"Shah","sequence":"first","affiliation":[{"name":"Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A","family":"Joslyn","sequence":"additional","affiliation":[{"name":"Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Lai","sequence":"additional","affiliation":[{"name":"Internal Medicine\/ Section of Geriatrics, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,12,9]]},"reference":[{"key":"2025082711460938000_14.12.e246571.1","unstructured":"LiverTox . Clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012."},{"key":"2025082711460938000_14.12.e246571.2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1080\/00365521.2017.1291719","article-title":"Drug-Induced liver injury due to antibiotics","volume":"52","author":"Bj\u00f6rnsson","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"2025082711460938000_14.12.e246571.3","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/hep.28323","article-title":"Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports","volume":"63","author":"Bj\u00f6rnsson","year":"2016","journal-title":"Hepatology"},{"key":"2025082711460938000_14.12.e246571.4","doi-asserted-by":"crossref","first-page":"S720","DOI":"10.1093\/ofid\/ofy210.2062","article-title":"2409. drug-induced liver injury (DILI) in a national cohort of hospitalized patients treated with aztreonam and ceftazidime","volume":"5","author":"Saade","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2025082711460938000_14.12.e246571.5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5009\/gnl15114","article-title":"Drug-Induced liver injury: pattern recognition and future directions","volume":"10","author":"Haque","year":"2016","journal-title":"Gut Liver"},{"key":"2025082711460938000_14.12.e246571.6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17010014","article-title":"RUCAM in drug and herb induced liver injury: the update","volume":"17","author":"Danan","year":"2015","journal-title":"Int J Mol Sci"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-246571","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T18:46:18Z","timestamp":1756320378000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-246571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":6,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,9]]},"published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1136\/bcr-2021-246571"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-246571","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]}}}